Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.53 |
| ▸ | EGFR | P00533 | 8/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886732 | 0.90 | ERBB2 (0.45) | ERBB2EGFRSRC | |
| SCHEMBL30988720 | 0.88 | ERBB2 (0.53) | ERBB2EGFRSRCPIK3CDPIK3CA | |
| SCHEMBL24106812 | 0.87 | ERBB2 (0.43) | ERBB2EGFRSRC | |
| SCHEMBL23817334 | 0.84 | ERBB2 (0.40) | ERBB2EGFRSRCPIK3CDPIK3CA | |
| SCHEMBL23817186 | 0.84 | ERBB2 (0.40) | ERBB2EGFRSRCPIK3CDPIK3CA | |
| SCHEMBL3275840 | 0.82 | SRC (0.63) | ERBB2EGFRSRCPIK3CDPIK3CA | |
| SCHEMBL30988724 | 0.82 | ERBB2 (0.48) | ERBB2EGFRSRCPIK3CDPIK3CA | |
| SCHEMBL21886741 | 0.81 | PIK3CD (0.46) | ERBB2EGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30988799 | 0.81 | PIK3CD (0.46) | ERBB2EGFRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30988743 | 0.81 | ERBB2 (0.47) | ERBB2EGFRSRCPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119317625-A | Crystalline forms of quinazoline derivatives, preparation, compositions and uses thereof | 豪夫迈·罗氏有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4360713-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| CN-112654612-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2020057511-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ERBB2 29/4885EGFR 117/4885SRC 93/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | ERBB2 29/4885EGFR 117/4885SRC 93/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ERBB2 29/4885EGFR 117/4885SRC 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.